AOD 9604 – Growth Hormone Fragment Research Peptide

1. Product Overview

AOD 9604 is a synthetic peptide fragment derived from the C‑terminal region (176–191) of human growth hormone (hGH), with specific sequence modifications to focus on metabolic activity rather than broad growth-related effects. It is used in research to study growth hormone fragment biology, particularly in the context of fat metabolism and energy regulation.

Typical research applications for AOD 9604 include:

• Investigation of adipocyte function and lipid turnover
• Studies of energy balance and body-composition–related pathways
• Structure–activity analyses of growth hormone fragments
• Comparative signaling studies versus full-length hGH

For research use only. Not for human or veterinary use.

2. Mechanistic Profile

AOD 9604 is a C‑terminal growth hormone fragment developed to explore fragment-specific metabolic actions distinct from classical GH receptor–IGF‑1 signaling.

Fragment-Associated Metabolic Cascade (Conceptual)

Although precise receptor targets remain under active investigation, experimental evidence suggests that AOD 9604 may:

1. Engage signaling mechanisms influenced by the C‑terminal tail of hGH.
2. Modulate intracellular pathways governing lipid mobilization and storage in adipocytes.
3. Influence kinase- and potentially cAMP-linked signaling routes, in a manner that differs from intact hGH.
4. Promote a shift toward increased lipid turnover and/or altered fat deposition in certain models.
5. Do so with relatively reduced activation of canonical GH–IGF‑1 pathways compared to full-length growth hormone.

This mechanistic profile underpins its use in:

• Studies of GH fragment selectivity and domain-specific actions
• Research on adipose tissue biology and metabolic signaling
• Explorations of how GH-derived peptides affect energy homeostasis

All mechanistic statements refer to research settings and are not clinical claims.

3. Structural & Chemical Data

• Peptide Type: Synthetic fragment corresponding to the hGH 176–191 region, with defined modifications
• Class: Short linear peptide (growth hormone fragment analog)
• Biological Origin: Conceptually derived from human pituitary growth hormone

Typical characteristics:

• Approximate Length: Short peptide (on the order of 15–20 amino acids)
• Approximate Molecular Mass: ~1.5–2.0 kDa (exact mass is sequence-specific)

AOD 9604 is designed to:

• Retain C‑terminal features of hGH implicated in lipid and energy metabolism
• Minimize broader anabolic or mitogenic activities associated with intact hGH

For precise sequence and molecular weight, refer to the lot-specific Certificate of Analysis (CoA).

4. Analytical Characterization (HPLC / MS)

HPLC

• AOD 9604 is typically purified to ≥ 98 % by High-Performance Liquid Chromatography (HPLC).
• Retention time and peak shape are checked against validated internal peptide standards to ensure batch consistency.

MS

• Identity is confirmed by mass spectrometry (MS / LC‑MS):
• Measured molecular ion matches the expected mass for the specified AOD 9604 sequence.
• Fragmentation spectra can be used to confirm sequence and structural integrity as needed.

This analytical framework supports use in:

• Mechanistic cell-based and biochemical assays
• Peptide quantification and assay validation
• Comparative evaluations across GH fragment analogs

5. Key Research Uses

5.1 Adipocyte Metabolism & Lipid Handling

AOD 9604 is frequently used in:

• In vitro models of adipocyte lipid mobilization and storage
• Experiments assessing lipolysis vs. lipogenesis under peptide exposure
• Studies examining how GH fragments modulate fat cell signaling independently of full-length GH

These studies often assess:

• Expression and activity of lipid-metabolizing enzymes
• Intracellular signaling pathways linked to fatty acid uptake, storage, and oxidation

5.2 Energy Balance & Metabolic Pathways

In metabolic research, AOD 9604 serves as a tool for:

• Probing energy expenditure and substrate utilization in experimental systems
• Examining the interplay between GH fragments and glucose/lipid homeostasis
• Distinguishing metabolic responses to C‑terminal GH fragments vs. full-length hGH

This may involve:

• Transcriptomic, proteomic, or metabolomic profiling under AOD 9604 exposure
• Time-course studies of downstream metabolic pathway modulation

5.3 Growth Hormone Fragment Structure–Function Analysis

Because AOD 9604 is derived from a defined region of hGH, it is utilized in:

• Domain mapping of growth hormone to identify sequence segments critical for metabolic actions
• Comparing multiple GH fragments to delineate specific structure–function relationships
• Informing the rational design of new GH fragment analogs for research use

Such work enhances understanding of:

• Which GH regions are most relevant for adipocyte and metabolic effects
• How modifications to the C‑terminal sequence impact signal specificity and potency

5.4 Peptide Pharmacology, Stability & Analytics

AOD 9604 can also act as a model peptide for:

• Stability studies (e.g., proteolytic degradation, temperature sensitivity)
• Formulation research, including solvent compatibility and adsorption to labware
• Development of quantitative analytical methods (LC‑MS/MS, immunoassays) for GH fragments

Note: AOD 9604 is supplied only for laboratory research. It is not intended for diagnostic, therapeutic, or veterinary applications.

6. Storage – Sublimated AOD 9604

6.1 Vacuum Sublimation & Shipping

AOD 9604 is manufactured using a Vacuum Sublimation (Controlled Dehydration) process and provided as a sublimated peptide powder.

Vacuum sublimation (controlled sublimation):

• The peptide is frozen under controlled conditions.
• It is exposed to reduced atmospheric pressure.
• Moisture in the peptide matrix transitions directly from solid to vapor phase.
• The result is a stable, amorphous powder structure known as a sublimated peptide.

In this form:

• AOD 9604 remains completely stable for shipping for approximately 4–6 months, provided it is kept dry and away from excessive heat.

The sublimated powder may be held at ambient laboratory temperature before reconstitution with sterile phosphate buffer, subject to the storage guidance below.

6.2 Storage Before Reconstitution

Upon receipt, AOD 9604 should be stored under controlled environmental conditions and kept away from humidity.

Recommended practices:

• Short- to mid-term use (days → several weeks/months):
• Refrigerated storage at 2–4°C is generally appropriate.
• Sublimated peptides are typically stable at room temperature for 4–6 weeks or more, provided they remain sealed, dry, and protected from light.
• If the peptide will not be reconstituted within 5–7 weeks, refrigerated storage at 2–4°C is recommended.
• Long-term storage (8 months → 3 years):
• Store in a cryogenic freezer at -70°C (-94°F).
• For multi-month or multi-year storage, cryogenic preservation best preserves the peptide’s structural stability and minimizes degradation.

6.3 Storage After Reconstitution

After AOD 9604 has been reconstituted with sterile phosphate buffer:

• Store at 2–4°C to maintain stability.
• Under these refrigerated conditions, reconstituted peptide solutions generally remain stable for up to 14 days.

Recommended:

• Reconstitute only the amount needed for near-term experiments.
• Keep bulk material in dry sublimated form for maximal shelf-life.
• Validate solution stability under your specific buffer composition, peptide concentration, and assay design.

7. Handling & Best Practices

7.1 General Handling

• Store AOD 9604 in a cool, dry, dark environment.
• Avoid repeated freeze–thaw cycles by preparing appropriate aliquots.
• Minimize exposure to ambient humidity; keep containers tightly closed.
• Shield from direct light, especially strong or UV light sources.

7.2 Preventing Humidity & Oxidation

• When removing from cold storage, allow vials to reach room temperature before opening to prevent condensation.
• Open containers only briefly and reseal promptly after removing the desired amount.
• Where possible, store residual material under a dry, inert gas atmosphere (e.g., nitrogen or argon).
• Use pre-aliquoted vials to limit handling and thermal cycling.

7.3 Storage in Solution

• Peptide solutions have shorter stability than dry powders and are more vulnerable to degradation.
• If solution storage is required:
• Use sterile phosphate buffer or other validated sterile buffers.
• Store at 2–4°C and use within 14 days, unless further stability is demonstrated.
• Prepare small aliquots to avoid re-freezing the same solution repeatedly.

7.4 Storage Containers

• Containers should be:
• Clean and chemically inert
• Appropriately sized to minimize headspace and limit moisture ingress

Suitable choices:

• Glass vials – excellent for long-term storage, chemically inert.
• Polypropylene vials – resistant to breakage, widely used for peptide storage.

Transfers between container types (e.g., from shipping vial to storage vial) should be performed under low-humidity, clean conditions.

8. Scientific Context & Acknowledgment

AOD 9604 is part of ongoing research into growth hormone fragment pharmacology, aiming to separate:

• Metabolic and adipocyte-directed effects of GH
• From classical growth and IGF‑1–mediated actions of full-length hormone

Research on GH fragments such as AOD 9604 has:

• Helped map functional domains within the GH molecule
• Supported the concept of domain-selective modulation of hormone action
• Provided examples of how peptide fragments can be used to study targeted endocrine effects

This context is offered solely to place AOD 9604 within the scientific framework of GH fragment research.
It is not a clinical recommendation or promotional statement.
No endorsement, sponsorship, or affiliation with any specific researcher or institution is implied.

9. Notes on Literature & References

To explore published data on AOD 9604 and related GH fragments, researchers may consult:

• Endocrinology and metabolism journals
• Peptide chemistry and pharmacology publications
• Obesity and adipocyte biology literature

Recommended database search terms include:

• “AOD 9604 growth hormone fragment”
• “GH 176–191 fragment adipocyte”
• “growth hormone C-terminal peptide metabolic”
• “GH fragment energy expenditure”

Access to full articles via PubMed, Scopus, or Web of Science will help align experimental designs with existing data.